

Amdocs Limited

NASDAQ: DOX

Fiscal Q2 2026 Earnings Presentation

May 13, 2026

Shimie Hortig

President & CEO

Tamar Rapaport-Dagim

Chief Financial Officer &
Chief Operating Officer

Forward-Looking Statement

The information contained herein in this presentation or delivered or to be delivered to you during this presentation does not constitute an offer, expressed or implied, or a recommendation to do any transaction in Amdocs Limited securities or in any securities of its affiliates or subsidiaries.

This presentation and the comments made by members of Amdocs management in conjunction with it can be found on the Investor Relations section of our website, and, as always, a copy of today's prepared remarks will also be posted immediately following the conclusion of this call. This presentation includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' strategy, including with respect to artificial intelligence and agentic opportunities, growth, financial outlook and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks, uncertainties and other important factors that may cause future results to differ materially from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers, Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025 filed on December 15, 2025, and for the first quarter of fiscal 2026 on February 17, 2026.

This presentation includes non-GAAP financial measures, including non-GAAP operating margin, free cash flow, revenue on a constant currency basis, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited, and non-GAAP earnings per share. Free cash flow equals cash generated by operating activities less net capital expenditures. While in prior years Amdocs used normalized free cash flow, Amdocs is no longer reporting normalized free cash flow. Normalized free cash flow is not comparable to free cash flow. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs' results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs' results of operations in conjunction with the corresponding GAAP measures. Please refer to the appendix for a reconciliation of these metrics to the most comparable GAAP provision. Amdocs believes that these measures provide useful information to investors and management regarding financial and business trends relating to its financial condition and results of operations, as well as the net amount of cash generated by its business operations after taking into account capital spending required to maintain or expand the business.

This presentation also includes pro forma metrics which exclude the financial impact of OpenMarket (divested on December 31, 2020) from fiscal year 2021. Please also review the information contained in Amdocs' press release dated May 13, 2026, with respect to earnings for fiscal Q2 2026. The press release contains additional information regarding Amdocs' outlook for fiscal year 2026 and certain non-GAAP metrics and their reconciliations.

Today's speakers



Shimie Hortig

President & Chief Executive Officer



Tamar Rapaport-Dagim

Chief Financial Officer & Chief Operating Officer

Agenda



Strategy & Business Performance Update

Shimie Hortig

President & Chief Executive Officer

Financial Review & Outlook

Tamar Rapaport-Dagim

Chief Financial Officer & Chief Operating Officer

Q&A



Shimie Hortig

President & Chief Executive Officer

Strategy and Business Performance Update

Today's focus

1

Future Vision

Become the **primary partner of choice** to our customers in their **agentic journey**

2

Q2 Overview & Outlook

Financial & operating performance highlights and financial outlook

1

Future Vision

1 A glimpse of our vision

Amdocs is **best positioned** to turn the **agentic vision** into reality for our customers



Deep industry knowledge
& domain expertise



Engineering &
innovation pedigree




Leader in mission-critical
systems transformation



Outcome-based
business model

1 Amdocs Agentic Strategy Building Blocks



1 aOS - Successful MWC 2026 launch & initial commercial traction



aOS Officially Launched
at Mobile World Congress
in Barcelona



Commercial Momentum

cricket

LUMEN

Bell

ECHOSTAR

PLDT

2

Q2 Overview & Outlook

2 Q2 Financial Highlights



Revenue

\$1.17B

Above guidance
midpoint



**Non-GAAP
operating margin**⁽¹⁾

21.5%

Up **20bps**
YoY



**Non-GAAP
EPS**⁽¹⁾

\$1.78

Above guidance
midpoint



**12-Month
Backlog**

\$4.28B

Up **\$30m** QoQ
Up **2.6%** YoY

Highlights:



**Year-over-year
revenue growth** in
North America



**Record revenue
quarter** in Europe



Strong performance
in Rest of World

2 Q2 commercial progress

cricket
Dealer onboarding modernization & managed services

LUMEN
Cloud transformation

 Spain
CRM & OSS modernization and long-term support

kt
Charging system modernization & operations

 **SETAR**
Mediation platform & BSS modernization

elisa
Managed services extension and expansion

ECHOSTAR
Charging operations

Our cloud-based platform solutions **continue to generate customer traction**

 **ConnectX**
VANTA U.S. Leading operator: Singapore **Quétal** MOBILE U.S.

 **eSIM**
cielo Brazil **mobifone** Vietnam

2 Q2 project execution & delivery

Key milestones



Mainframe to cloud migration



Commercial launch of digital transformation



Digital transformation



E2E OSS go live for Wireline, enabling Network Fulfillment and Orchestration including Network Inventory Management



- **AT&T 5G SA** on Next-Gen Charging
- **AT&T's OneConnect plan launch**



Platform hardware migration completed



Successful Network Inventory Management rollout



Successful platform upgrade



Fulfillment of B2B cloud migration

2 On track to achieve FY26 financial guidance



Revenue⁽¹⁾

2.0% - 4.0%

YoY growth

- Reiterate **3.0% midpoint** in constant currency⁽¹⁾



Free cash flow⁽³⁾

\$710m - \$730m

- Reiterate **\$720m midpoint**
- **~90%** earning-to-cash flow conversion, and attractive free cash flow yield⁽³⁾⁽⁴⁾ of **~10%**



Non-GAAP EBIT⁽²⁾

21.3% - 21.9%

% margin

- Reiterate **21.6% midpoint**
- Up **20bps** YoY



Non-GAAP EPS⁽²⁾

5.0% - 7.0%

YoY growth

- Reiterate **6.0% midpoint**

1. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period

2. Non-GAAP. See reconciliation tables in appendix

3. Excludes restructuring related payments

4. Yield = expected free cash flow of \$720M, the midpoint of FY2026 FCF guidance, as a percentage of Amdocs' market capitalization as of 05/13/2026

Bringing it all together

1

We believe **Amdocs is best positioned** to turn the **agentic vision** into reality for our customers

2

Shaping our strategic direction based on the vision and direction; **initial traction with aOS**

3

Solid Q2 financial results in line with our guidance

4

Commercial and operational progress with important wins and key project milestones delivered

5

Reiterating midpoint of FY26 guidance, while closely monitoring the macroeconomic environment and customer spend

CFO transition



Tamar Rapaport-Dagim

Chief Financial Officer &
Chief Operating Officer

Retiring after a remarkable 19-year tenure as CFO, the past 8 years as both CFO and COO, and 22 years at Amdocs overall



On behalf of all of us, Tamar, please accept our sincere appreciation for your **endless dedication and service to Amdocs** through the years and we wish you nothing but the best on your well-deserved retirement

-Shimie Hortig, Amdocs CEO



Tal Rozenfeld

GM, Head of Finance
CPA | MA in Law

CFO effective June 1, 2026

- A proven business performer with an impressive **20-year career at Amdocs**, spanning senior roles in accounting, finance and as division business leader for APAC
- Currently GM & Head of Finance, overseeing the **entire finance organization**



I've known Tal for his entire career at Amdocs, and having worked closely with him on many occasions, I am well aware of his **great leadership** qualities. I strongly believe he is the **best fit** for this role. Congratulations Tal, and welcome to my leadership team.

-Shimie Hortig, Amdocs CEO



Tamar Rapaport Dagim


Chief Financial Officer & Chief Operating Officer

Financial Review & Outlook

Solid Q2 FY2026 Financial Results

Q2 2026 Revenue vs. Guidance

\$ Millions



Revenue above guidance midpoint, including a favorable foreign currency movement of roughly \$2M compared to guidance

Key Metrics:

Revenue

\$1,172m

+3.9% YoY as reported

+2.2% YoY constant currency⁽¹⁾

Non-GAAP⁽²⁾ Operating Margin

21.5%

+20 bps YoY, -10 bps QoQ

GAAP Diluted EPS


\$1.28, above guidance midpoint (\$1.22 - \$1.30)

Non-GAAP⁽²⁾ Diluted EPS

\$1.78, above guidance midpoint (\$1.73 - \$1.79)

Q2 2026 Revenue by Region

\$ Millions



North America ~ +2.2% YoY


Record revenue in Europe
~ +6.2% YoY

Healthy trends in Rest of World
~ +8.0% YoY

1. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period
2. Non-GAAP. See reconciliation tables in appendix

Managed Services

Supporting visibility and business resilience



**managed services
contract renewals**

Managed services arrangements support business model resiliency with highly recurring revenue streams, multi-year engagements and high renewal rates, and may also include large-scale digital transformation projects

Expanded and extended managed services contract with Cricket Wireless for BSS and OSS services, including aOS capabilities, driving faster time to market and improved customer experience.

Strong Balance Sheet & Cash Flow

\$800M commercial paper program launched March 2026 to further enhance financial flexibility and short-term funding mix, supported by revolving credit facility which was upsized to \$800M from \$500M previously.

Cash + Available Credit Facility
\$844 million


Ample liquidity to support ongoing business needs while retaining the capacity to fund future strategic growth

Baa1
Moody's

BBB
S&P

Committed to maintaining our investment grade credit rating


Cash, Credit Facility & Debt Position
 \$ Millions, as of March 31, 2026



1. Non-GAAP. See reconciliation tables in appendix
2. Short-term financing arrangements as of March 31, 2026: \$170M drawn on \$800M revolving credit facility, upsized from \$500M previously, leaving \$630M available; \$80M on call under an uncommitted bank line of credit
3. \$650M senior note, maturing June 2030;

Q2 2026 Free cash flow⁽¹⁾ bridge

FCF before restructuring payments of \$17M was **\$97M** in Q2



*Figures may not sum due to rounding

DSO's
73 days


-4 days YoY and -3 days QoQ
 DSO's may fluctuate from quarter to quarter

Unbilled receivables net of deferred revenue decreased by **\$42 million** compared to a year ago and by **\$2 million** sequentially in Q2, aggregating the short-term and long-term balances

The net difference between unbilled receivables and deferred revenue fluctuates from quarter to quarter, in line with normal business activities as well as progress on multi-year transformation programs

Disciplined Capital Allocation


FCF: Six-year historical trend and FY2026E outlook



FY 2026 free cash flow⁽¹⁾ target
reiterated: \$710-\$730M
 (before restructuring payments)

~90% Earnings to cash conversion
~10% Free cash flow yield⁽²⁾

1. Non-GAAP. See appendix tables for reconciliation of FCF
 2. Yield = expected free cash flow of \$720M, the mid point of FY2026 FCF guidance before restructuring payments, as a percentage of Amdocs' market capitalization as of 5/13/2026
 3. FCF in FY2020, FY2021 and FY2022 is presented on a normalized basis, which mainly excludes net capital expenditures related to the new campus development; normalized FCF disclosure is not applicable as of FY2023 onward



Dividend

Board authorized quarterly dividend payment:

56.9 cents

Payable July 31, 2026

Share Repurchase Authorization

~\$0.7B aggregate remaining share
 repurchase authorization

4. Refer to <https://investors.amdocs.com/> and earnings reports issued on 11/2/2021 and 11/8/2022 for reconciliation of normalized FCF in FY2020, FY2021 and FY2022
 5. FY2023, FY2024, and FY2025, exclude restructuring payments of ~\$20M, ~\$75M, ~\$90M, respectively
 6. FY2026 assumes midpoint of \$710-\$730M guidance range, before restructuring payments

Leading Indicators & Visibility: 12-month Backlog


12-Month Backlog

Up **\$30M** QoQ

\$4.28B

Up **2.6%** YoY

Quarterly 12-Month Backlog Growth YoY %



12-month backlog includes:


- Anticipated revenue related to contracts
- Estimated revenue from **managed services** contracts
- Letters of intent
- Maintenance**
- Estimated **ongoing support** activities

1. For comparison purposes, pro forma adjusts quarterly revenue from Q124 to Q4F24 by approximately \$150 million, and fiscal 2024 revenue by approximately \$600 million, to reflect the end of certain low margin, non-core business activities; these activities substantially already ceased in the first quarter fiscal 2025 and were not included in the full year fiscal 2025 revenue outlook

FY2026 Revenue Growth Outlook

Revenue Growth

YoY% Growth Constant Currency⁽³⁾



FY2026 revenue growth:

Outlook tightened to 2.0%-4.0% YoY constant currency⁽³⁾


- Expects **2.6%-4.6%** as reported, including a foreign currency benefit of 60 bps compared with 50 bps previously
- Roughly half of the expected growth in fiscal 2026 expected to be inorganic in nature

1. For comparison purposes, pro forma fiscal 2024 revenue by approximately \$600 million to reflect the end of certain low margin, non-core business activities; these activities substantially already ceased in the first quarter fiscal 2025 and are not included in the full year fiscal 2025 revenue outlook
2. Pro forma metrics exclude the financial impact of OpenMarket (which was divested on December 31, 2020) from fiscal year 2021.
3. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period

Sustained Margin Expansion in FY2026

Balancing strategic growth investments with ongoing cost and efficiency benefits

Annual Non-GAAP⁽¹⁾ Operating Margin: FY2020 – FY2026E⁽²⁾



+20 bps YoY at the midpoint of the FY2026 target range of 21.3%-21.9%

Balancing generative AI growth investments against the benefits of internal cost and efficiency improvements

Operating margin may fluctuate slightly between quarters

1. Non-GAAP. See reconciliation tables in appendix
2. Refer to <https://investors.amdocs.com/> and earnings reports issued on 11/10/20, 11/2/2021, 11/8/2022, 11/7/2023, 11/12/2024 and 11/11/2025 for reconciliation of non-GAAP operating margin in FY2018, FY2019, FY2020, FY2021, FY2022, FY2023, FY2024 and FY2025

FY2026 Non-GAAP Diluted EPS Growth Outlook


Tightening the range, reiterating the midpoint

Total Shareholder Return⁽³⁾⁽⁴⁾

Non-GAAP⁽²⁾ Diluted EPS Growth YoY % + Dividend Yield

Non-GAAP⁽²⁾ EPS growth outlook tightened to **5.0%-7.0%** in FY2026E

6% midpoint guidance unchanged compared with prior outlook



***Non-GAAP⁽²⁾ EPS growth of 6.0%, plus 2.7% dividend yield⁽³⁾**

1. Pro forma metrics exclude the financial impact of OpenMarket (which was divested on December 31, 2020) from fiscal year 2021.
2. Non-GAAP. See reconciliation tables in appendix
3. Expected total shareholder return assumes Non-GAAP EPS growth plus dividend yield (based on fiscal year end closing share price); FY2026E assumed 6.0% midpoint of non-GAAP EPS outlook, and dividend yield based on quarterly rate of \$0.569 as of share price on 11/11/25
4. Refer to <https://investors.amdocs.com/> and earnings reports issued on 11/10/2020, 11/2/2021, 11/8/2022, 11/7/2023, 11/12/2024 and 11/11/2025 for non-GAAP reconciliation in FY2020, FY2021, FY2022, FY2023, FY2024 and FY2025

Q&A

Appendix

Outlook & Reconciliation Tables

Q3 & FY2026 Outlook

1. Non-GAAP. See reconciliation tables in appendix. Free cash flow outlook is before expected restructuring payments
2. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period

Q3 Fiscal 2026 Outlook

Revenue	\$1,155 - \$1,195 million
GAAP EPS	\$1.39 - \$1.47
Non-GAAP⁽¹⁾ EPS	\$1.81 - \$1.87
Share Count	106 million
Tax	Non-GAAP effective tax rate within the annual guidance range of 16.0%-19.0% in Q3 specifically

FY 2026 Outlook	Updated	Previous
Revenue growth As reported	2.6% - 4.6%	1.5% - 5.5%
Revenue growth Constant currency ⁽²⁾	2.0% - 4.0%	1.0% - 5.0%
GAAP EPS Growth	12.0% - 15.0%	10.0% - 17.0%
Non-GAAP⁽¹⁾ EPS growth	5.0% - 7.0%	4.0% - 8.0%
Operating Margin Non-GAAP ⁽¹⁾	21.3% - 21.9%	21.3% - 21.9%
Effective Tax Rate Non-GAAP ⁽¹⁾	16.0% - 19.0%	16.0% - 19.0%
Free Cash Flow	\$710-\$730 million	\$710-\$730 million

Reconciliation Tables

- a) The amounts under "Purchase of property and equipment, net", include immaterial proceeds from sale of property and equipment for the three and six months ended March 31, 2026 and 2025, respectively.

AMDOCS LIMITED Selected Financial Metrics (In thousands, except per share data)

	Three months ended March 31,		Six months ended March 31,	
	2026	2025	2026	2025
Revenue	\$ 1,171,979	\$ 1,128,203	\$ 2,327,918	\$ 2,238,258
Non-GAAP operating income	251,836	240,106	501,775	475,504
Non-GAAP net income	192,501	201,017	389,632	389,894
Non-GAAP net income attributable to Amdocs Limited	191,544	200,259	387,787	388,417
Non-GAAP diluted earnings per share	\$ 1.78	\$ 1.78	\$ 3.59	\$ 3.44
Diluted weighted average number of shares outstanding	107,472	112,514	107,997	112,981

Free Cash Flows (In thousands)

	Three months ended March 31,		Six months ended March 31,	
	2026	2025	2026	2025
Net Cash Provided by Operating Activities	\$ 101,584	\$ 172,458	\$ 321,766	\$ 278,013
Purchases of property and equipment, net (a)	(21,237)	(15,964)	(53,476)	(43,319)
Free Cash Flow	\$ 80,347	\$ 156,494	\$ 268,290	\$ 234,694

Reconciliation Tables

AMDOCS LIMITED Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP (In thousands)

	Three Months Ended March 31, 2026							Non-GAAP
	GAAP	Amortization of purchased intangible assets and other	Equity based compensation expense	Changes in certain acquisitions related liabilities measured at fair value	Restructuring charges	Other	Tax effect	
Operating expenses:								
Cost of revenue	\$ 716,733	\$ -	\$ (11,392)	\$ (135)	\$ -	\$ -	\$ -	\$705,206
Research and development	87,001		(2,068)					84,933
Selling, general and administrative	153,677		(24,539)	866				130,004
Amortization of purchased intangible assets and other	21,308	(21,308)						-
Restructuring charges	10,405				(10,405)			-
Total operating expenses	989,124	(21,308)	(37,999)	731	(10,405)	-	-	920,143
Operating income	182,855	21,308	37,999	(731)	10,405			251,836
Interest and other expense, net	(5,963)					(7,637)		(13,600)
Income taxes	38,120						7,615	45,735
Net income	138,772	21,308	37,999	(731)	10,405	(7,637)	(7,615)	192,501
Net income attributable to noncontrolling interests	957							957
Net income attributable to Amdocs Limited	\$ 137,815	\$ 21,308	\$ 37,999	\$ (731)	\$ 10,405	\$ (7,637)	\$ (7,615)	\$191,544

	Three Months Ended March 31, 2025							Non-GAAP
	GAAP	Amortization of purchased intangible assets and other	Equity based compensation expense	Changes in certain acquisitions related liabilities measured at fair value	Other	Tax effect		
Operating expenses:								
Cost of revenue	\$ 698,049	\$ -	\$ (12,356)	\$ (360)	\$ -	\$ -	\$ -	\$685,333
Research and development	81,796		(2,283)					79,513
Selling, general and administrative	134,625		(11,014)	(360)				123,251
Amortization of purchased intangible assets and other	15,998	(15,998)						-
Restructuring charges	-							-
Total operating expenses	930,468	(15,998)	(25,653)	(720)	-	-	-	888,097
Operating income	197,735	15,998	25,653	720				240,106
Interest and other expense, net	(8,465)				(69)			(8,534)
Income taxes	25,269					5,286		30,555
Net income	164,001	15,998	25,653	720	(69)	(5,286)		201,017
Net income attributable to noncontrolling interests	758							758
Net income attributable to Amdocs Limited	\$ 163,243	\$ 15,998	\$ 25,653	\$ 720	\$ (69)	\$ (5,286)		\$200,259

Reconciliation Tables

AMDOCS LIMITED Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP (In thousands)

	Six Months Ended March 31, 2026							
	GAAP	Amortization of purchased intangible assets and other	Equity based compensation expense	Changes in certain acquisitions related liabilities measured at fair value	Restructuring charges	Other	Tax effect	Non-GAAP
Operating expenses:								
Cost of revenue	\$ 1,444,456	\$ -	\$ (22,765)	\$ (494)	\$ -	\$ -	\$ -	\$ 1,421,197
Research and development	168,979		(3,927)					165,052
Selling, general and administrative	267,398		(35,397)	7,893				239,894
Amortization of purchased intangible assets and other	35,842	(35,842)						-
Restructuring charges	21,706				(21,706)			-
Total operating expenses	1,938,381	(35,842)	(62,089)	7,399	(21,706)	-	-	1,826,143
Operating income	389,537	35,842	62,089	(7,399)	21,706			501,775
Interest and other expense, net	(17,228)					(6,064)		(23,292)
Income taxes	75,083						13,768	88,851
Net income	297,226	35,842	62,089	(7,399)	21,706	(6,064)	(13,768)	389,632
Net income attributable to noncontrolling interests	1,845							1,845
Net income attributable to Amdocs Limited	\$ 295,381	\$ 35,842	\$ 62,089	\$ (7,399)	\$ 21,706	\$ (6,064)	\$ (13,768)	\$ 387,787

	Six Months Ended March 31, 2025							
	GAAP	Amortization of purchased intangible assets and other	Equity based compensation expense	Changes in certain acquisitions related liabilities measured at fair value	Restructuring charges	Other	Tax effect	Non-GAAP
Operating expenses:								
Cost of revenue	\$ 1,380,308	\$ -	\$ (25,606)	\$ (360)	\$ -	\$ -	\$ -	\$ 1,354,342
Research and development	166,129		(4,554)					161,575
Selling, general and administrative	256,712		(22,013)	12,138				246,837
Amortization of purchased intangible assets and other	31,757	(31,757)						-
Restructuring charges	6,783				(6,783)			-
Total operating expenses	1,841,689	(31,757)	(52,173)	11,778	(6,783)	-	-	1,762,754
Operating income	396,569	31,757	52,173	(11,778)	6,783			475,504
Interest and other expense, net	(14,874)					5,979		(8,895)
Income taxes	65,842						10,873	76,715
Net income	315,853	31,757	52,173	(11,778)	6,783	5,979	(10,873)	389,894
Net income attributable to noncontrolling interests	1,477							1,477
Net income attributable to Amdocs Limited	\$ 314,376	\$ 31,757	\$ 52,173	\$ (11,778)	\$ 6,783	\$ 5,979	\$ (10,873)	\$ 388,417



Thank you!